Medical advances are leading to more new therapeutics but it is small biotech rather than Big Pharma that stands to gain the most. We meet the developers of promising medicines currently breaking into the market to find out whether it is time for the giants to move aside.
We also look at the Gates Foundation’s new collaboration for the research of new TB drugs, ask why Alzheimer’s researchers are turning back to previously discarded drugs, and find out if the discovery of an enzyme that gradually counteracts the efficacy of antipsychotic drugs could lead to the development of a more effective schizophrenia treatment. Moreover, we check in on the progress of major international research projects and investigate changing trends in early phase clinical trials.
In this issue
Small Players Big Drugs Big Pharma has never been renowned for innovation. Rather, large pharmaceutical companies have traditionally focused on developing and testing conventional therapeutics. Medical advances are leading to more novel therapeutics and it is small biotech that stands to gain the most. Click here to read the full article.
Pushing for a BreakthroughAlzheimer’s disease affects 18 million people worldwide but a cure continues to evade scientists. With access to new data and research platforms our understanding of the illness continues to increase. Dr Nicola Davies finds out how close we are to a breakthrough. Click here to read the full article.
New PathUS researchers have discovered an enzyme in the brain of schizophrenia sufferers that counteracts the effects of antipsychotic drugs. Pharmaceutical Technology Focus investigates whether this breakthrough research could lead to a cure. Click here to read the full article.
Tackling TBAt any given moment, more than 12 million people are suffering from active TB, which is the second leading infectious cause of death worldwide with 1.4 million people dying from it in 2010. The TB Drug Accelerator Project’s Dr Carl Nathan explains how a new partnership aims to find a reliable treatment for the disease. Click here to read the full article.
Partnerships that Ease the Pain The Innovative Medicines Initiative plans to call for new proposals for major research projects. Executive Director Michel Goldman outlines how ongoing projects are reporting significant breakthroughs and demonstrating the success of large-scale public-private partnerships. Click here to read the full article.
Changing TrendsEarly-phase clinical trials are crucial for establishing proof of concept and pharmaceutical companies conduct trials every few years. However, with reduced timelines and more detailed patient selection criteria the world of phase I and II trials is rapidly changing. Click here to read the full article.
Next Issue Preview
Cloud-based computing and virtualisation software hold the key to truly integrated supply chain management. In the next issue we check out the latest IT tools revolutionising the supply chain for pharmaceuticals.
We also find out how security can be managed better to prevent medical cargo theft, and look at the new EC directive for good distribution practice, the push for continuous temperature monitoring, and how the industry can achieve more effective cold chains.
Moreover, we explore logistical problems faced by distributors moving sensitive drugs across the African continent, and look at the challenges of transporting emergency aid and healthcare to conflict zones in the Middle East.
Digital Magazine FAQ
The digital magazine is viewable on any computer with Flash Player installed. It is also viewable on mobile devices, iPhones and iPads, although some features and videos may be disabled.